KIF5B
KIF5B (Kinesin-1 heavy chain) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Neuroendocrine tumours and 2 more.
Overview
Microtubule-dependent motor required for normal distribution of mitochondria and lysosomes. Can induce formation of neurite-like membrane protrusions in non-neuronal cells in a ZFYVE27-dependent manner. Regulates centrosome and nuclear positioning during mitotic entry.
Open Targets scores its association with cancer at 0.81 (direct and indirect evidence; datatypes clinical 0.97, affected pathway 0.93, literature 0.91, genetic association 0.00, somatic mutation 0.82). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Head and Neck Squamous Cell Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · KIF5B (Kinesin-1 heavy chain) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Neuroendocrine tumours and 2 more.
- 1 · What it is
KIF5B (Kinesin-1 heavy chain) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Neuroendocrine tumours and 2 more.
- 2 · What goes wrong in cancer
Microtubule-dependent motor required for normal distribution of mitochondria and lysosomes. Can induce formation of neurite-like membrane protrusions in non-neuronal cells in a ZFYVE27-dependent manner.
- 3 · How drugs use it
No product in this corpus aims at KIF5B yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:6324 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P33176 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000170759 (association with cancer (MONDO_0004992) 0.81; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.72, thyroid cancer 0.64, neuroendocrine neoplasm 0.63, lung cancer 0.73 (GraphQL API, CC0)); IntOGen KIF5B (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Microtubule-dependent motor required for normal distribution of mitochondria and lysosomes. Can induce formation of neurite-like membrane protrusions in non-neuronal cells in a ZFYVE27-dependent manner. Regulates centrosome and nuclear positioning during mitotic entry. During the G2 phase of the cell cycle in a BICD2-dependent manner, antagonises dynein function and drives the separation of nuclei and centrosomes. Required for anterograde axonal transportation of MAPK8IP3/JIP3 which is essential for MAPK8IP3/JIP3 function in axon elongation. Through binding with PLEKHM2 and ARL8B, directs lysosome movement toward microtubule plus ends. Location: Cytoplasm, cytoskeleton; Cytolytic granule membrane; Lysosome membrane (UniProt). Locus 10p11.22 (HGNC).
- Lung cancer: Open Targets association 0.73 with lung cancer (MONDO_0008903)
- Thyroid cancer: Open Targets association 0.64 with thyroid cancer (MONDO_0002108)
- Neuroendocrine tumours: Open Targets association 0.63 with neuroendocrine neoplasm (MONDO_0019496)
- Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)
- Non-small-cell lung cancer: Open Targets association 0.72 with non-small cell lung carcinoma (MONDO_0005233)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.97; IntOGen calls it an activating (Act) driver in 1 cohort. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"KIF5B" OR ABSTRACT:"KIF5B" OR TITLE:"kinesin family member 5B" OR ABSTRACT:"kinesin family member 5B" OR TITLE:"Kinesin-1 heavy chain" OR ABSTRACT:"Kinesin-1 heavy chain" OR TITLE:"uKHC" OR ABSTRACT:"uKHC" OR TITLE:"KNS1" OR ABSTRACT:"KNS1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KIF5B, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCCDC6
Shares Thyroid cancer, Lung cancer (all types), Neuroendocrine tumours, IntOGen.
- TargetEML4
Shares Thyroid cancer, Lung cancer (all types), Open Targets Platform, Non-small-cell lung cancer.
- TargetEPHA7
Shares Thyroid cancer, Neuroendocrine tumours, IntOGen, Open Targets Platform.
- TargetLRIG3
Shares Lung cancer (all types), IntOGen, Open Targets Platform, Non-small-cell lung cancer.
- TargetNKX2-1
Shares Thyroid cancer, Lung cancer (all types), IntOGen, Open Targets Platform.
- TargetSTRN
Shares Thyroid cancer, Lung cancer (all types), Open Targets Platform.
- TargetEPHA1
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
- TargetEPHA10
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.